At a glance
ClinicalIndex Comparison RecordPhase 2Active· 16 enrolled
Drug / intervention
RYZ101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates and/or Chemotherapy (TRACY-1).
In Brief
A Phase 2 clinical trial evaluating RYZ101 for Metastatic Breast Cancer and 3 related conditions. Active but no longer recruiting, targeting 16 participants across 31 sites in 3 countries.
Detailed Summary
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
CountriesCanada, South Korea, United States
Collaborators--
Timeline
Phase 2Active
202520262027202820292030203120322033
Enrollment StartJul 2024
First PostedSep 2024
TodayJul 2026
Primary CompletionOct 2028
Study CompletionJan 2033
First PostedSep 19, 2024
Enrollment StartJul 19, 2024
Primary CompletionOct 1, 2028
Study CompletionJan 1, 2033
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 1.8 years agoPrimary completion in 2.2 years
Interventions
RYZ101drug
Ac-225